mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.085 |
0.01 |
mRNA |
PF-4800567 hydrochloride |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
0.01 |
mRNA |
BRD-K41597374 |
CTRPv2 |
pan-cancer |
AAC |
0.086 |
0.02 |
mRNA |
ABT-737 |
CTRPv2 |
pan-cancer |
AAC |
-0.087 |
0.02 |
mRNA |
IU1 |
CTRPv2 |
pan-cancer |
AAC |
0.091 |
0.02 |
mRNA |
selumetinib:navitoclax (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.084 |
0.02 |
mRNA |
AZD7762 |
CTRPv2 |
pan-cancer |
AAC |
-0.075 |
0.02 |
mRNA |
BRD-K97651142 |
CTRPv2 |
pan-cancer |
AAC |
0.085 |
0.03 |
mRNA |
decitabine:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.07 |
0.03 |
mRNA |
navitoclax:piperlongumine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.081 |
0.03 |